Showing results (31-40 of 128) with videos related to
Sort By:
Pageof 13
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2021
The Quest for an Accurate Functional Tumor Volume with 68Ga-DOTATATE PET/CTRyan P Reddy, C Ross Schmidtlein, Romina G Giancipoli, et al.Pediatric Blood & Cancer|February 1, 2011
Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trialGrazyna Wrobel, Audrey Mauguen, Angelo Rosolen, et al.Retina (Philadelphia, Pa.)|February 28, 2020
TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µgAlbert Liao, Terry Hsieh, Jasmine H Francis, et al.BMC Medical Research Methodology|April 19, 2015
Validation of death prediction after breast cancer relapses using joint modelsAudrey Mauguen, Bernard Rachet, Simone Mathoulin-Pélissier, et al.Plos One|July 2, 2020
Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastomaTerry Hsieh, Albert Liao, Jasmine H Francis, et al.Vaccines|June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer VaccineIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 5, 2023
Long-Term Prognostic Value of 82Rb PET/CT-Determined Myocardial Perfusion and Flow Reserve in Cancer PatientsJosef J Fox, Audrey Mauguen, Kimiteru Ito, et al.Neuro-Oncology|July 10, 2010
Neuronal differentiation distinguishes supratentorial and infratentorial childhood ependymomasFelipe Andreiuolo, Stéphanie Puget, Matthieu Peyre, et al.International Journal of Cancer|February 11, 2026
A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remissionBrian H Kushner, Shakeel Modak, Charlie White, et al.International Journal of Cancer|January 10, 2026
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remissionBrian H Kushner, Charlie White, Audrey Mauguen, et al.Pageof 13